Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImage Scan Holdings Regulatory News (IGE)

Share Price Information for Image Scan Holdings (IGE)

Share Price is delayed by 15 minutes
Get Live Data
2.00    -0.15 (-6.98%)
Bid:
1.90
Ask:
2.10
Spread: 0.20 (10.526%)
Market Cap: £2.74m
IGE Live PriceLast checked at - London Stock Exchange

Intraday Image Scan Holdings Share Chart

Interim Results

30 Apr 2026 07:00

RNS Number : 4734C
Image Scan Holdings PLC
30 April 2026
 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

30 April 2026

Image Scan Holdings plc

("Image Scan", the "Company" or the "Group")

Interim Results

Image Scan, (AIM: IGE), the specialist supplier of X-ray screening systems to the security and industrial inspection markets, today announces its interim results for the six months ended 31 March 2026.

 

For further information on the Company, please visit: www.ish.co.uk and for further information on its products, please visit: www.3dx-ray.com

 

-ENDS-

 

Image Scan Holdings plc Tel: +44 (0) 1509 817400

Vincent Deery CEO

Sarah Atwell-King, CFO & Company Secretary

 

 

Zeus - Nominated Advisor and Corporate Broker  Tel: +44 (0)203 829 5000

Mike Coe/James Bavister (Investment Banking)

 

About Image Scan Holdings plc

The core activity of the Group is the manufacture of portable X-ray systems for security and counter terrorism applications. The Group recently launched a cabinet X-ray machine and is replacing its Axis range of checkpoint X-ray systems with new machines developed with a partner. All these products are taken to market across the world through a strong network of international partners.

 

In addition, over the last seventeen years, Image Scan has developed and manufactured industrial X-ray inspection systems, the MDXi range. The primary market for these systems is in automotive emissions control where they are used for quality control inspection of catalytic converters and diesel particulate filters.

 

The visibility and reach of the Company's 3DX-Ray brand has been further strengthened through a new LinkedIn profile focussed on its EOD and counter-terrorism activities. This can be found at: https://www.linkedin.com/company/3dx-ray/

 

For further information on the Company, please visit: www.ish.co.uk - and for further information on its products, please visit: www.3dx-ray.com

 

 

 

Chief Executive Officer's statement

Introduction

Image Scan Holdings plc is a specialist in innovative X-ray technology, operating globally in the security and industrial inspection sectors. The Company's principal activity is the design, manufacture, and supply of both portable and fixed X-ray security screening systems to governments, security organisations and law enforcement agencies. The Company also supplies high-quality screening systems used in the manufacture of catalytic converters and diesel particulate filters.

 

Financial results

Revenue for the period was £1,321k (H1 2025: £350k). Gross profit increased from £205k to £679k despite the % margin decreasing due to the change in product mix.

Operating expenses were £608k (H1 2025: £630k), reflecting the benefit of cost control measures initiated in FY25.

The increase in sales to more typical historic levels, which along with the controlled costs, led to a pre-tax profit of £75k in H1 2026 (H1 2025: pre-tax loss off £422k).

The Company finished H1 2026 with an order book up 44% to £1,265k (H1 2025: £879k[1]).

At the period end, the Company had a cash balance up 86% to £955k (H1 2025: £512k) and no debt.

Review of the period

During the first half of FY26, the Group delivered a markedly improved financial performance compared with the same period last year, reflecting a return to more normalised trading conditions and the successful conversion of opportunities developed during FY25.

The stabilisation in market conditions and improved customer confidence during H1 FY26 has been notable. Revenue for the period was largely driven by higher activity levels across the business, evidenced by increased order flow through the Group's international partner network.

 

The Company announced in February that the UK defence programme subcontracted via NP Aerospace (the "NPA contract") which had already been subject to delays had been terminated for convenience by the end customer. While extremely disappointing it did not arise from any failure by NP Aerospace or Image Scan to meet contractual obligations and was not performance‑related. The Company continues to work constructively with NP Aerospace to draw the matter to an orderly conclusion).

Pleasingly, order book, excluding the NPA contract, has improved and reflects a strengthening pipeline of opportunities across the security and defence markets, with growing traction for higher‑specification solutions within the ThreatScan AS range.

During the period, the Company was actively involved in a number of international exhibitions and end‑user demonstrations across multiple regions. These activities have supported increased market engagement with standard quote activity up by over 40% reinforces a more positive outlook for the year as a whole, subject to contract timing.

Cash and cost discipline remained a priority throughout the period and is evidenced by the Group's period‑end cash position and return to pre‑tax profitability

 

Outlook

The Company enters the second half of FY26 in a stronger position than at the same point last year, supported by improved trading momentum, a solid order book and an opportunity pipeline across multiple geographies.

While geopolitical and macroeconomic uncertainty remains elevated and continues to influence customer behaviour and procurement timing, current activity levels across the Group's core markets are materially higher than those experienced during FY25. The Board remains encouraged by increasing engagement in higher‑value tenders, ongoing partner‑led demonstrations and the strengthening of the Group's product offering.

The Board remains focused on disciplined execution, margin management and selective investment to support sustainable growth. While the full-year outcome remains dependent on the timing and delivery of second-half orders, the Board believes the operational and commercial progress achieved in H1 provides a credible basis for a significantly improved full‑year outcome compared with FY25.

.

 

 

Vince Deery

Chief Executive Officer

 

Consolidated income statement

For the six months ended 31 March 2026

 

Note

Six months

ended

31 March 2026

(Unaudited)

£'000

Six months

ended

31 March 2025

(Unaudited)

£'000

Year ended

30 September

 2025

 

(Audited)

£'000

 

Revenue

1,321

350

1,617

Cost of sales

(642)

(155)

(671)

Gross profit

679

205

946

Gross profit %

51%

59%

58%

Operating expenses

(608)

(630)

(1,238)

Operating profit/(loss)

71

(425)

(292)

Finance income

5

5

8

Interest payable

(1)

(2)

(4)

Profit/(loss) before taxation

75

(422)

(288)

Taxation

-

-

-

Profit/(loss) for the period

75

(422)

(288)

 

Pence

Pence

Pence

Earnings per share

Basic profit/(loss) per share

[3]

0.06

(0.30)

(0.21)

Diluted profit/(loss) per share

0.06

(0.30)

(0.21)

 

 

 

Consolidated statement of changes in equity

For the six months ended 31 March 2026

 

Note

Six months

ended

31 March 2026

(Unaudited)

£'000

Six months

ended

31 March 2025

(Unaudited)

£'000

Year ended

30 September

 2025

(Audited)

£'000

Opening equity shareholders' funds

1,431

1,719

1,719

Profit/(loss) attributable to equity shareholders

75

(422)

(288)

Closing equity shareholders' funds

1,506

1,297

1,431

 

 

Consolidated statement of financial position

As at 31 March 2026

 

As at

31 March 2026

(Unaudited)

£'000

As at

31 March 2025

(Unaudited)

£'000

As at

30 September

 2025

(Audited)

£'000

Non-current assets

Intangible and tangible assets

347

481

390

347

481

390

Current assets

 

Inventories

432

489

374

Trade and other receivables

632

302

422

Cash and cash equivalents

995

512

1,131

2,059

1,303

1,927

Total assets

2,406

1,784

2,317

Current liabilities

 

Trade and other payables

877

394

841

Non-current liabilities

23

93

45

Total liabilities

900

487

886

Net assets

1,506

1,297

1,431

 

 

Equity

 

Share capital

1,368

1,368

1,368

Share premium account

8,333

8,333

8,333

Retained earnings

(8,195)

(8,404)

(8,270)

Equity shareholders' funds

1,506

1,297

1,431

 

 

Consolidated cash flow statement

For the six months ended 31 March 2026

 

Six months

ended

31 March 2026

(Unaudited)

£'000

Six months ended 31 March 2025 (Unaudited) £'000

Year ended

30 September

 2025

(Audited)

£'000

Cash flows from operating activities

Operating profit/(loss)

71

(424)

(292)

Adjustments for:

 

 

Amortisation of intangibles

43

32

66

Amortisation of right of use asset

23

21

46

Impairment of inventories

26

23

32

Increase in inventories

(85)

(119)

(13)

(Increase)/decrease in trade and other receivables

(209)

605

488

Increase/(decrease) in trade and other payables

12

(451)

(15)

Increase/(decrease) in provision for warranty

1

(11)

(10)

Net cash (used in)/generated from operating activities

(273)

(324)

302

Corporation tax recovered

-

-

-

Net cash (outflow)/ inflow from operating activities

(273)

(324)

302

 

Cash flows from investing activities

 

Interest received

5

5

8

Purchase of intangible assets

-

(57)

(43)

Net cash generated/(used) in investing activities

5

(52)

(35)

 

Cash flows from financing activities

 

 

Lease payments

(23)

(23)

(47)

Net cash used in financing activities

(23)

(23)

(47)

 

 

Net (decrease)/increase in cash and cash equivalents

(136)

(399)

220

Cash and cash equivalents at beginning of period

1,131

911

911

Cash and cash equivalents at end of period

995

512

1,131

 

 

Notes to the unaudited interim financial statements

For the six months ended 31 March 2026

 

1 Basis of preparation

The interim financial statements, which are unaudited, have been prepared on the basis of the accounting policies expected to apply for the financial year to 30 September 2026 and in accordance with recognition and measurement principles of International Financial Reporting Standards ('IFRSs') as adopted by the United Kingdom. The accounting policies applied in the preparation of these interim financial statements are consistent with those used in the financial statements for the year ended 30 September 2025.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim financial reporting'. Accordingly, whilst the interim statements have been prepared in accordance with IFRSs, they cannot be construed as being in full compliance with IFRSs.

 

The financial information for the year ended 30 September 2025 does not constitute the full statutory accounts for that period. The annual report and financial statements for the year ended 30 September 2025 have been filed with the Registrar of Companies. The independent auditor's report on the report and financial statements for the year ended 30 September 2025 was unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under Section 498(2) or 498(3) of the Companies Act 2006.

 

2 Going concern

The interim financial information has been prepared on a going concern basis, which assumes that the Company will have adequate resources to continue in operational existence for the foreseeable future.

 

3 Earnings per share ('EPS')

Basic earnings per ordinary share is based on the loss on ordinary activities before taxation of £75k (H1 2025 loss £422k) and on 136,854,577 ordinary shares in issue throughout the period.

 

Diluted profit per share is calculated by adjusting the weighted average number of ordinary shares in issue on the assumption of conversion of dilutive potential ordinary shares, based on the share price at the end of the period. The Company's dilutive potential ordinary shares are shares issued under the Company's Enterprise Management Incentive ('EMI') scheme and options issued under the Company's Unapproved scheme.

 

 


[1] Excluding the NPA contract

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FLFERSRIAFIR
Date   Source Headline
5th Jun 20269:45 amRNSContract Award
30th Apr 20267:00 amRNSInterim Results
25th Feb 20262:27 pmRNSResult of AGM
25th Feb 20267:00 amRNSAGM Statement
2nd Feb 20267:00 amRNSUpdate on Defence Contract with NP Aerospace
21st Jan 20261:31 pmRNSNotice of AGM and Posting of Annual Report
2nd Dec 20257:00 amRNSFinal Results
18th Nov 20257:00 amRNS-RContract Award
11th Nov 20257:00 amRNSNew Contract Award
4th Nov 20257:00 amRNSTrading Update
2nd Sep 202511:23 amRNSHolding(s) in Company
21st Aug 20257:00 amRNSTrading Update And New Contract Awards
20th May 20258:32 amRNSInterim Results
14th May 202511:55 amRNSHolding(s) in Company
26th Feb 20252:38 pmRNSResult of AGM
26th Feb 20257:00 amRNSAGM Statement
15th Jan 202510:48 amRNSNotice of AGM & Posting of Annual Report
3rd Dec 20247:00 amRNSFinal Results
23rd Oct 20247:00 amRNSTrading Update
16th Oct 20247:00 amRNSContract Award Update
4th Sep 20247:00 amRNSHolding(s) in Company
21st Aug 20247:00 amRNSHolding(s) in Company
7th Aug 20247:00 amRNSHolding(s) in Company
5th Aug 20247:00 amRNSHolding(s) in Company
24th Jul 20247:00 amRNSHolding(s) in Company
15th Jul 20247:00 amRNSChange of Adviser
4th Jul 20247:00 amRNSContract Award
12th Jun 20247:00 amRNSContract award worth over £350k
20th May 20244:33 pmRNSHolding(s) in Company
30th Apr 20247:00 amRNSInterim Results
29th Apr 20247:00 amRNSInitial c£300k order for new Portable X-Ray System
12th Mar 20247:00 amRNSLaunch of AXIS-CXi Cabinet with AI Software
28th Feb 20242:48 pmRNSResult of AGM
28th Feb 20247:00 amRNSTrading Statement
26th Jan 20241:50 pmRNSHolding(s) in Company
18th Jan 20241:28 pmRNSHolding(s) in Company
11th Jan 20243:06 pmRNSHolding(s) in Company
9th Jan 202412:46 pmRNSNotice of AGM & Posting of Annual Report
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSFinal Results
10th Oct 20237:00 amRNSTrading Update
11th Sep 20237:00 amRNS2023 orders to over 30 countries
4th Jul 20237:00 amRNSHolding(s) in Company
26th Apr 20237:00 amRNSInterim Results
13th Mar 20239:34 amRNSHolding(s) in Company
28th Feb 20233:03 pmRNSResult of AGM
28th Feb 20237:00 amRNSTrading Statement
10th Feb 20231:26 pmRNSHolding(s) in Company
26th Jan 202312:09 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.